An investigation of biomarkers derived from legacy microarray data for their utility in the RNA-seq era

Abstract

BackgroundGene expression microarray has been the primary biomarker platform ubiquitously applied in biomedical research, resulting in enormous data, predictive models, and biomarkers accrued. Recently, RNA-seq has looked likely to replace microarrays, but there will be a period where both technologies co-exist. This raises two important questions: Can microarray-based models and biomarkers be directly applied to RNA-seq data? Can future RNA-seq-based predictive models and biomarkers be applied to microarray data to leverage past investment?ResultsWe systematically evaluated the transferability of predictive models and signature genes between microarray and RNA-seq using two large clinical data sets. The complexity of cross-platform sequence correspondence was considered in the analysis and examined using three human and two rat data sets, and three levels of mapping complexity were revealed. Three algorithms representing different modeling complexity were applied to the three levels of mappings for each of the eight binary endpoints and Cox regression was used to model survival times with expression data. In total, 240,096 predictive models were examined.ConclusionsSignature genes of predictive models are reciprocally transferable between microarray and RNA-seq data for model development, and microarray-based models can accurately predict RNA-seq-profiled samples; while RNA-seq-based models are less accurate in predicting microarray-profiled samples and are affected both by the choice of modeling algorithm and the gene mapping complexity. The results suggest continued usefulness of legacy microarray data and established microarray biomarkers and predictive models in the forthcoming RNA-seq era.Electronic supplementary materialThe online version of this article (doi:10.1186/s13059-014-0523-y) contains supplementary material, which is available to authorized users.

Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression

“…Importantly, this association is present also in a patient dataset (SEQC) containing 498 sequenced NB tumors (Fig. 5 D-F) (19,20), whereas HIF1α shows no correlation with these factors, neither in the treated LAN-1 tumors nor in the SEQC dataset (Fig. 5 G-L).…”

“…To investigate how genes regulated by AZA+RA treatment at D14 correlate with clinical parameters, we performed k-means clustering on the SEQC 498 patient dataset (19,20). Genes significantly (adjusted P < 0.05) increased (UP) or decreased (DOWN) with ≥ twofold difference upon AZA+RA treatment at D14 were used to group the NB dataset.…”

An overview on potential of in vitro studies and transcriptomics for cancer

“…Conclusively we can say that RNA-Seq and microarraybased models are comparable and can be used in clinical endpoint prediction for cancer or other diseases. This prediction refers to any abnormality or symptom that constitutes one of the target outcomes of the trial [51,52].…”

The Role of Transcriptomics: Physiological Equivalence Based on Gene Expression Profiles

“…Genome-wide analysis has boosted the biomarker diagnostics industry and contributes to disease subtype classification, disease diagnosis and prognosis, selection of therapeutic treatments, and disease prevention (He et al, 2006;Sun et al, 2013;Su et al, 2014;Aibar et al, 2015).…”

“…Additional advantages of RNA-seq include low background noise, large and dynamic signal range, and detection with no requirement for prior sequence information. More recently, RNA-seq has emerged as the preferred approach for genome-wide expression analysis Rowley et al, 2011;Su et al, 2014) . 3. Transcriptomics for physiological difference DNA microarray and RNA-seq technology provide a wide range of novel application opportunities relating to gene expression profiles, which can be applied to various studies.…”